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DruQuaR 
1. GC-FID 
• Five different batches of a fusafungine market preparation 
• Determination of EtOH and IPM concentration 
 
2. Franz Diffusion Cell (FDC) 
• Buccal pig mucosa 
• Dose solutions: 1 mg/mL enniatins mix in different EtOH:IPM mixtures 
 1:99, 3:97, 5:95 and 10:90 EtOH:IPM (V/V) 
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1. Determination of EtOH and IPM content 
• EtOH: 1.67 ± 0.03% (mean ± SEM, n =5) 
• IPM: 91.60 ± 2.02% (mean ± SEM, n =5) 
• No statistical significant difference between batches (p > 0.10) 
 
2. Transmucosal kinetics 
• Enniatins able to permeate buccal mucosa! 













• No statistical significant difference between dose solutions (p > 0.05) 
• Inverse relationship between log P versus kp,v, tlag and Q8h  
• Local mucosa concentrations up to 33 μM (total enniatins) 
        marketed preparations  x 10 dosage = 330 μM  
• Enniatins in topical medicines are capable of permeating the mucosa barrier! 
• QbD approach  no risk of a significantly different systemic enniatin availability in terms of composition variability. 
• Worst-case scenario  question use of enniatins in topical treatment of innocent upper respiratory tract infections  long-term chronic effects? 
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REFERENCES 
Enniatin R1 R2 R3 
Enniatin A III III III 
Enniatin A1 III I III 
Enniatin B I I I 
Enniatin B1 I III I 
Enniatin C II II II 
Enniatin D I I II 
Enniatin E1 I II III 
Enniatin E2 I III II 
Enniatin F II III III 
FUSAFUNGINE 
• Mixture of cyclic hexadepsipeptide enniatins 
• Produced by fungi, i.a. Alternaria and Fusarium 
• Marketed as oral/nasal sprays, patented in 1953 
• Topical treatment of upper respiratory tract infections 
• Claimed anti-inflammatory and bacteriostatic effects 
• SmPC indicates no systemic absorption 
1. Do enniatins permeate mucosa and reach blood circulation? 
2. Influence of excipient variability on mucosal permeation? 
 Quantify transmucosal kinetics 
MUCOSA 
? 
• Enniatins have been shown to permeate human skin 
• Generally mucosal permeation > skin permeation 
• Formulated in ethanol (EtOH) and isopropyl myristate (IPM) 
3. UHPLC-MS/MS (MRM) 




• Transmucosal kinetics 
• Steady-state plasma concentrations 
Donor chamber 




EtOH:IPM (V/V) 1:99 3:97 5:95 10:90 1:99 3:97 5:95 10:90 
2° parameters Jss (ng/(cm²×h)) Q8h (%) 
ENN B 20.11 ± 2.00 15.16 ± 1.98 21.24 ± 1.76 19.43 ± 2.13 0.048 ± 0.006 0.035 ± 0.005 0.053 ± 0.005 0.053 ± 0.007 
ENN B1 5.54 ± 0.79 3.45 ± 0.62 5.96 ± 0.73 5.36 ± 0.93 0.018 ± 0.003 0.014 ± 0.002 0.020 ± 0.003 0.021 ± 0.004 
ENN A1 0.68 ± 0.12 0.56 ± 0.16 0.90 ± 0.19 0.81 ± 0.12 0.006 ± 0.001 0.006 ± 0.002 0.008 ± 0.002 0.008 ± 0.001 
ENN D 1.13 ± 0.14 6.79 ± 0.12 1.18 ± 0.10 1.16 ± 0.16 0.034 ± 0.005 0.024 ± 0.004 0.033 ± 0.004 0.038 ± 0.006 
ENN E 0.22 ± 0.04 0.14 ± 0.02 0.24 ± 0.04 0.22 ± 0.04 0.014 ± 0.003 0.011± 0.002 0.015 ± 0.003 0.014 ± 0.002 
1° parameters kp,v (× 10
-5 cm/h) Lag time (h) 
ENN B 4.36 ± 0.43 3.25 ± 0.43 4.75 ± 0.40 4.68 ± 0.51 1.24 ± 0.22 1.56 ± 0.16 0.93 ± 0.20 0.94 ± 0.19 
ENN B1 1.62 ± 0.23 1.06 ± 0.19 1.79 ± 0.22 1.87 ± 0.32 1.16 ± 0.24 0.73 ± 0.21 1.13 ± 0.05 0.93 ± 0.08 
ENN A1 0.50 ± 0.08 0.43 ± 0.12 0.67 ± 0.14 0.70 ± 0.11 0.67 ± 0.38 n.d. 0.53 ± 0.20 0.68 ± 0.21 
ENN D 3.04 ± 0.39 2.14 ± 0.33 2.95 ± 0.25 3.47 ± 0.48 1.20 ± 0.14 1.31 ± 0.09 0.94 ± 0.18 1.16 ± 0.13 
ENN E 1.20 ± 0.22 0.80 ± 0.14 1.36 ± 0.21 1.45 ± 0.30 0.86 ± 0.12 0.50 ± 0.11 0.92 ± 0.05 0.86 ± 0.12 
3. Clinical interpretation 
• Neglecting in-vivo saliva flow, GI absorption, metabolisation 
• Steady-state plasma concentrations 
 
   Cpl,ss,buccal = (A × kp,v × Cv)/Cl 
 
   Cl = plasma clearance 
   kp,v = transmucosal permeability coefficient 
   Cv = enniatin concentration in vehicle 
   A = exposed mucosal area 
 
• Ranging from 0.026 mg/L for ENN E to 1.339 mg/L for ENN B 
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